Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials.

ABSTRACT:

Background

Despite their efficacy in improving positive symptoms, first- and second-generation antipsychotics (FGAs and SGAs) fail to provide benefit to a large portion of patients with schizophrenia. Evenamide, uniquely acting at the site of dysfunction, normalizes hippocampal glutamatergic aberrant activity and reduces downstream hyperdopaminergic state, potentially alleviating also negative and cognitive symptoms, and providing benefit to patients with treatment-resistant schizophrenia (TRS) or inadequate response to antipsychotics (APs).

Objectives

Evaluate the clinical benefits of glutamate modulation through evenamide as an add-on treatment to FGAs and SGAs in patients with TRS or inadequate response to APs.

Design

Post-hoc analyses of results from two phase II/

SUBMITTER: Anand R 

PROVIDER: S-EPMC12835518 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature